fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Tobramycin

Form:

6 of 6 products shown

5 general benefit · 1 Limited Use

Tobrex · DIN 00614254 · 0.3% · Oph Oint

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Tobrex · DIN 00614254 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-08-02 · brand TOBREX · ATC S01AA12 TOBRAMYCIN · form Ointment · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/W · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tobrex: Formulary list price $2.75 per unit (the source does not state the unit; exact figure $2.7514). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00614254)

Source record
DIN 00614254: Tobrex Raw flags: sec3=Y Item: 520404024; group id 584; item number 1539; lccId None; manufacturer id NOV Source form: Oph Oint; strength: 0.3% Recorded listing: General benefit Source prices (unrounded): $2.7514; ministry $2.7514 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00614254 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5707
Shortage status: resolved shortage (ended February 23, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00614254
Shortage record checked October 6, 2026

Sandoz Tobramycin · DIN 02241755 · 0.3% · Oph Sol

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Sandoz Tobramycin · DIN 02241755 Manufacturer: Sandoz Canada Inc.; listing date 2002-04-04 Health Canada: Marketed since 2005-10-08 · brand SANDOZ TOBRAMYCIN · ATC S01AA12 TOBRAMYCIN · form Solution · route Ophthalmic · ingredients TOBRAMYCIN 0.3 % · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tobramycin: Formulary list price $1.36 per unit (the source does not state the unit; exact figure $1.3620). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02241755)

Source record
DIN 02241755: Sandoz Tobramycin Raw flags: sec3=Y Item: 520404020; group id 584; item number 1540; lccId None; manufacturer id SDZ Source form: Oph Sol; strength: 0.3% Recorded listing: General benefit Source prices (unrounded): $1.3620; ministry $1.3620 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241755 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65418
Interchangeable products
Tobrex · DIN 00513962 · $1.3620
Shortage status: resolved shortage (ended October 24, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241755
Shortage record checked October 6, 2026

Tobrex · DIN 00513962 · 0.3% · Oph Sol

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Tobrex · DIN 00513962 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-09-10 · brand TOBREX · ATC S01AA12 TOBRAMYCIN · form Solution · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00513962)

Source record
DIN 00513962: Tobrex Raw flags: sec3=Y Item: 520404020; group id 584; item number 1540; lccId None; manufacturer id NOV Source form: Oph Sol; strength: 0.3% Recorded listing: General benefit Source prices (unrounded): $1.9400; ministry $1.3620 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00513962 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4571
Interchangeable products
Sandoz Tobramycin · DIN 02241755 · $1.3620
Shortage status: resolved shortage (ended February 4, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00513962
Shortage record checked October 6, 2026

TOBI Podhaler · DIN 02365154 · 28 mg · Inh Pd-capsule

Limited Use, Reason for Use code 472 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 472 required
Write on scriptReason for Use code 472 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 472
Reason for Use code 472 For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
TOBI Podhaler · DIN 02365154 Manufacturer: BGP Pharma ULC; listing date 2016-06-29 Health Canada: Marketed since 2020-03-11 · brand TOBI PODHALER · ATC J01GB01 TOBRAMYCIN · form Capsule · route Inhalation · ingredients TOBRAMYCIN 28 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

TOBI Podhaler: Formulary list price $14.69 per unit (the source does not state the unit; exact figure $14.6911). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02365154)

Source record
DIN 02365154: TOBI Podhaler Raw flags: sec12=Y, sec3=Y Item: 081228163; group id 50; item number 0107; lccId 00265; manufacturer id BGP Source form: Inh Pd-Cap; strength: 28mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.6911; ministry $14.6911 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02365154 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85000
Shortage status: resolved shortage (ended March 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02365154
Shortage record checked October 6, 2026

TOBI · DIN 02239630 · 300 mg/5 mL · Inh Sol-5mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
TOBI · DIN 02239630 Manufacturer: BGP Pharma ULC; listing date 2006-10-23 Health Canada: Marketed since 2021-10-06 · brand TOBI · ATC J01GB01 TOBRAMYCIN · form Solution · route Inhalation · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 300 MG/5ML · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239630)

Source record
DIN 02239630: TOBI Raw flags: sec3=Y Item: 081228094; group id 51; item number 0108; lccId None; manufacturer id BGP Source form: Inh Sol-5mL Pk; strength: 300mg/5mL Recorded listing: General benefit Source prices (unrounded): $64.5832; ministry $41.0985 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239630 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63101 Therapeutic Notes (formulary) For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.
Interchangeable products
Teva-Tobramycin · DIN 02389622 · $41.0985
Shortage status: resolved shortage (ended September 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239630
Shortage record checked October 6, 2026

Teva-Tobramycin · DIN 02389622 · 300 mg/5 mL · Inh Sol-5mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Tobramycin · DIN 02389622 Manufacturer: Teva Canada Limited; listing date 2016-03-30 Health Canada: Marketed since 2016-02-03 · brand TEVA-TOBRAMYCIN · ATC J01GB01 TOBRAMYCIN · form Solution · route Inhalation · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 60 MG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Tobramycin: Formulary list price $41.10 per unit (the source does not state the unit; exact figure $41.0985). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02389622)

Source record
DIN 02389622: Teva-Tobramycin Raw flags: sec3=Y Item: 081228094; group id 51; item number 0108; lccId None; manufacturer id TEV Source form: Inh Sol-5mL Pk; strength: 300mg/5mL Recorded listing: General benefit Source prices (unrounded): $41.0985; ministry $41.0985 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02389622 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87512 Therapeutic Notes (formulary) For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.
Interchangeable products
TOBI · DIN 02239630 · $41.0985
Shortage status: resolved shortage (ended February 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389622
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01A, S01AA): coverage varies; not interchangeable

  • Framycetin (Soframycin): general benefit
  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Gatifloxacin (Zymar (with preservative)): not a benefit
  • Moxifloxacin (Vigamox): not a benefit

Tobramycin sulfate

3 general benefit · 1 not a benefit

Tobramycin · DIN 02241210 · 80 mg/2 mL · injection solution-2mL Pk

General benefitMarketed · checked November 16, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Tobramycin · DIN 02241210 Manufacturer: Sandoz Canada Inc.; listing date 2002-04-04 Health Canada: Marketed since 2005-08-26 · brand TOBRAMYCIN INJECTION USP · ATC J01GB01 TOBRAMYCIN · form Solution · route Intramuscular, Intravenous · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tobramycin: Formulary list price $3.15 per unit (the source does not state the unit; exact figure $3.1500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02241210)

Source record
DIN 02241210: Tobramycin Raw flags: sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id SDZ Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: General benefit Source prices (unrounded): $3.1500; ministry $3.1500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241210 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64816
Interchangeable products
Nebcin · DIN 00325449 · not recorded Tobramycin Injection USP · DIN 02502372 · $3.1500 Tobramycin Injection USP · DIN 02533103 · $3.1500
Shortage status: resolved shortage (ended February 8, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241210
Shortage record checked October 6, 2026

Tobramycin Injection USP · DIN 02502372 · 80 mg/2 mL · injection solution-2mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Tobramycin Injection USP · DIN 02502372 Manufacturer: Sterimax Inc.; listing date 2023-04-28 Health Canada: Marketed since 2021-02-17 · brand TOBRAMYCIN INJECTION USP · ATC J01GB01 TOBRAMYCIN · form Solution · route Intravenous, Intramuscular · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Sterimax inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tobramycin Injection USP: Formulary list price $3.15 per unit (the source does not state the unit; exact figure $3.1500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502372)

Source record
DIN 02502372: Tobramycin Injection USP Raw flags: sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id STE Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: General benefit Source prices (unrounded): $3.1500; ministry $3.1500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502372 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99195
Interchangeable products
Nebcin · DIN 00325449 · not recorded Tobramycin · DIN 02241210 · $3.1500 Tobramycin Injection USP · DIN 02533103 · $3.1500
Shortage status: resolved shortage (ended June 19, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502372
Shortage record checked October 6, 2026

Tobramycin Injection USP · DIN 02533103 · 80 mg/2 mL · injection solution-2mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Tobramycin Injection USP · DIN 02533103 Manufacturer: Jamp Pharma Corporation; listing date 2024-06-28 Health Canada: Marketed since 2024-05-16 · brand TOBRAMYCIN INJECTION USP · ATC J01GB01 TOBRAMYCIN · form Solution · route Intravenous, Intramuscular · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tobramycin Injection USP: Formulary list price $3.15 per unit (the source does not state the unit; exact figure $3.1500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02533103)

Source record
DIN 02533103: Tobramycin Injection USP Raw flags: sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id JPC Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: General benefit Source prices (unrounded): $3.1500; ministry $3.1500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02533103 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102212
Interchangeable products
Nebcin · DIN 00325449 · not recorded Tobramycin · DIN 02241210 · $3.1500 Tobramycin Injection USP · DIN 02502372 · $3.1500
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02533103
Shortage record checked October 6, 2026

Nebcin · DIN 00325449 · 80 mg/2 mL · injection solution-2mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-05-12 — choose a marketed DIN from the same-category list.Discontinued May 12, 2003 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-05-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-05-12 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Nebcin · DIN 00325449 Manufacturer: Eli Lilly Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2003-05-12 · brand NEBCIN INJ 40MG/ML · ATC J01GB01 TOBRAMYCIN · form Liquid · route Intravenous, Intramuscular · ingredients TOBRAMYCIN (TOBRAMYCIN SULFATE) 40 MG/ML · company Eli lilly canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Nebcin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00325449)

Source record
DIN 00325449: Nebcin Raw flags: notABenefit=Y, sec3=Y Item: 081228035; group id 52; item number 0109; lccId None; manufacturer id LIL Source form: Inj Sol-2mL Pk; strength: 80mg/2mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00325449 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2140
Interchangeable products
Tobramycin · DIN 02241210 · $3.1500 Tobramycin Injection USP · DIN 02502372 · $3.1500 Tobramycin Injection USP · DIN 02533103 · $3.1500
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00325449
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 12, 2003 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (S01A, S01AA): coverage varies; not interchangeable

  • Framycetin (Soframycin): general benefit
  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Gatifloxacin (Zymar (with preservative)): not a benefit
  • Moxifloxacin (Vigamox): not a benefit

Tobramycin & dexamethasone

Form:

2 of 2 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

TobraDex · DIN 00778915 · 0.3% & 0.1% · Oph Oint

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
TobraDex · DIN 00778915 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-04-26 · brand TOBRADEX · ATC S01CA01 DEXAMETHASONE AND ANTIINFECTIVES, S01CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Ointment · route Ophthalmic · ingredients DEXAMETHASONE 0.1 %/W/W, TOBRAMYCIN 0.3 %/W/W · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

TobraDex: Formulary list price $3.32 per unit (the source does not state the unit; exact figure $3.3171). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00778915)

Source record
DIN 00778915: TobraDex Raw flags: sec3=Y Item: 520404032; group id 585; item number 1541; lccId None; manufacturer id NOV Source form: Oph Oint; strength: 0.3% & 0.1% Recorded listing: General benefit Source prices (unrounded): $3.3171; ministry $3.3171 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00778915 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10971
Shortage status: resolved shortage (ended August 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778915
Shortage record checked October 6, 2026

TobraDex · DIN 00778907 · 0.3% & 0.1% · Oph suspension

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
TobraDex · DIN 00778907 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-05-10 · brand TOBRADEX · ATC S01CA01 DEXAMETHASONE AND ANTIINFECTIVES, S01CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/V, DEXAMETHASONE 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

TobraDex: Formulary list price $2.25 per unit (the source does not state the unit; exact figure $2.2500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00778907)

Source record
DIN 00778907: TobraDex Raw flags: sec3=Y Item: 520404031; group id 585; item number 1542; lccId None; manufacturer id NOV Source form: Oph Susp; strength: 0.3% & 0.1% Recorded listing: General benefit Source prices (unrounded): $2.2500; ministry $2.2500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00778907 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11068
Shortage status: resolved shortage (ended August 5, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778907
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01A, S01AA): coverage varies; not interchangeable

  • Framycetin (Soframycin): general benefit
  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Gatifloxacin (Zymar (with preservative)): not a benefit
  • Moxifloxacin (Vigamox): not a benefit
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL 08:12:28 Other Antibiotics

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)

RIFAXIMIN

· 1 products · Limited Use, codes 475 · strengths: 550mg · Tab

VANCOMYCIN HCL

· 4 products · Limited Use, codes 557, 558, 559, 560 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 125mg, 250mg · Cap

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 3 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles

Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN 52:04:04 Antibiotics

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free)

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

· 1 products · General benefit · strengths: 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

CIPROFLOXACIN AND DEXAMETHASONE

· 3 products · Limited Use, codes 509 · strengths: 0.3% w/v & 0.1% w/v · Otic Susp-7.5mL Pk (With Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TOBREX (Tobramycin Ophthalmic Solution, USP) and TOBREX (Tobramycin Ophthalmic Ointment, USP) are topical antibiotic preparations indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TOBREX and other antibacterial drugs, TOBREX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. https://pdf.hres.ca/dpd_pm/00055025.PDF PM date: February 12, 2020 Source product: TOBREX; DIN 00513962; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS Tobramycin Injection USP may be indicated for the treatment of the following infections when caused by susceptible organisms: septicemia, complicated and recurrent urinary tract infections, lower respiratory infections, serious skin and soft tissue infections including burns and peritonitis and central nervous system infections caused by organisms resistant to antibiotics usually considered efficacious in these infections. Tobramycin is usually active against most strains of the following organisms in vitro and in clinical infections: • Pseudomonas aeruginosa • Proteus sp. (indole-positive and indole-negative), including Proteus mirabilis, Morganella morganii, Providencia rettgeri, and Proteus vulgaris • Escherichia coli • Klebsiella-Enterobacter-Serratia group • Citrobacter sp. • Providencia sp. • Staphylococci, including Staphylococcus aureus (coagulase-positive and coagulase- negative) Tobramycin Injection USP may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacteria… https://pdf.hres.ca/dpd_pm/00085270.PDF PM date: July 7, 2026 Source product: TOBRAMYCIN INJECTION USP; DIN 02241210; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension and ointment) is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exist. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, thermal burns or penetration of foreign bodies. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TOBRADEX and other antibacterial drugs, TOBRADEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Pediatrics (< 18 years of age): The safety and effectiveness of TOBRADEX have not been established in pediatric patients. TOBRADEX® Product Monograph Page 3 of 28 https://pdf.hres.ca/dpd_pm/00055027.PDF PM date: February 12, 2020 Source product: TOBRADEX; DIN 00778907; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Nebcin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026